An update on the pharmacogenetics of treating hypertension

Journal of Human Hypertension

Volumn 29, Issue 5, 2015, Pages 283-291

  Fontana, V ^a   Luizon, M R ^b   Sandrim, V C ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CLINICAL TRIAL (TOPIC); EPIGENETICS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; ADVERSE DRUG REACTION; BLOOD PRESSURE; CLASSIFICATION; DRUG EFFECTS; DRUG RESISTANCE; GENETIC ASSOCIATION STUDY; GENETICS; GENOME-WIDE ASSOCIATION STUDY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84927759893     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2014.76     Document Type: Review

References (51)

1. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010; 24(5): 336-344.
2. Johnson JA. Advancing management of hypertension through pharmacoge-nomics. Ann Med 2012; 44(Suppl 1): S17-S22.
3. Menni C, Mangino M, Zhang F, Clement G, Snieder H, Padmanabhan S et al. Heritability analyses show visit-to-visit blood pressure variability reflects different pathological phenotypes in younger and older adults: evidence from UK twins. J Hypertens 2013; 31(12): 2356-2361.
4. Basson J, Simino J, Rao DC. Between candidate genes and whole genomes: time for alternative approaches in blood pressure genetics. Curr Hypertens Rep 2012; 14 (1): 46-61.
5. Munroe PB, Barnes MR, Caulfield MJ. Advances in blood pressure genomics. Circ Res 2013; 112(10): 1365-1379.
6. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J 2013; 34(13): 951-961.
7. Padmanabhan S, Newton-Cheh C, Dominiczak AF. Genetic basis of blood pressure and hypertension. Trends Genet 2012; 28(8): 397-408.
8. Toka HR, Koshy JM, Hariri A. The molecular basis of blood pressure variation. Pediatr Nephrol 2013; 28(3): 387-399.
9. Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther 2014; 95(5): 499-500.
10. Burt T, Dhillon S. Pharmacogenomics in early-phase clinical development. Pharmacogenomics 2013; 14(9): 1085-1097.
11. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92(4): 414-417.
12. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89(3): 464-467.
13. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens 2008; 21(1): 61-66.
14. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008; 52(2): 359-365.
15. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J 2013; 13(3): 257-263.
16. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013; 62(2): 391-397.
17. Svensson-Färbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. J Hypertens 2011; 29(2): 388-395.
18. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens 2013; 31(4): 698-704.
19. Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY et al. Hypertension susceptibility loci and blood pressure response to anti-hypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet 2012; 5(6): 686-691.
20. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41(3): 398-403.
21. Suonsyrjä T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. Am J Hypertens 2009; 22(2): 169-175.
22. Su X, Lee L, Li X, Lv J, Hu Y, Zhan S et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007; 115(6): 725-732.
23. Luo JQ, Wang LY, He FZ, Sun NL, Tang GF, Wen JG et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics 2013; 15(2): 201-208.
24. Mas S, Gassò P, Alvarez S, Ortiz J, Sotoca JM, Francino A et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics 2011; 21(9): 531-538.
25. Grilo A, Sáez-Rosas MP, Santos-Morano J, Sánchez E, Moreno-Rey C, Real LM et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 2011; 21 (1): 10-17.
26. Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002; 16(12): 857-863.
27. Mahmoudpour SH, Leusink M, van der Putten L, Terreehorst I, Asselbergs FW, de Boer A et al. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics 2013; 14(3): 249-260.
28. Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005; 77(4): 617-626.
29. Cilia La Corte AL, Carter AM, Rice GI, Duan QL, Rouleau GA, Adam A et al. A functional XPNPEP2 promoter haplotype leads to reduced plasma amino-peptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 2011; 32(11): 1326-1331.
30. Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Neth Heart J 2012; 20(1): 24-32.
31. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K et al. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 2008; 31(8): 1549-1557.
32. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 2012; 59(6): 1204-1211.
33. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445(1-2): 151-152.
34. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011; 89(5): 662-673.
35. Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Skaar TC et al. Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate. Clin Pharmacol Ther 2014; 96(2): 175-181.
36. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al. Pharma-cokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004; 76(6): 536-544.
37. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to meto-prolol. Clin Pharmacol Ther 2003; 74(1): 44-52.
38. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84(6): 715-721.
39. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 2011; 89 (3): 366-378.
40. Filigheddu F, Argiolas G, Degortes S, Zaninello R, Frau F, Pitzoi S et al. Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 2010; 11(3): 319-325.
41. Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG et al. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension 2012; 60(4): 957-964.
42. Kamide K, Asayama K, Katsuya T, Ohkubo T, Hirose T, Inoue R et al. Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. Pharmacogenomics 2013; 14(14): 1709-1721.
43. Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langaee TY et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics 2007; 17(9): 719-729.
44. Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J, Moss JI et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet 2009; 2(4): 362-370.
45. Hamrefors V, Sjögren M, Almgren P, Wahlstrand B, Kjeldsen S, Hedner T et al. Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms. J Hypertens 2012; 30(6): 1151-1160.
46. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18 (11): 1422-1428.
47. Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK. Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT. Int J Hypertens 2013; 2013: 578578.
48. Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR et al. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol 2011; 30(8): 555-564.
49. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2010; 10(1): 40-45.
50. Palei AC, Sandrim VC, Amaral LM, Machado JS, Cavalli RC, Lacchini R et al. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J 2012; 12(6): 489-498.
51. Luizon MR, Palei ACT, Sandrim VC, Amaral LM, Machado JSR, Lacchini R et al. Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J (e-pub ahead of print 10 June 2014; doi:10.1038/tpj.2014.26).